Glimepirid Actavis

Glimepirid Actavis is a prescription oral medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea used to manage blood glucose. It is marketed in the European Union and is supplied in tablet form, although specific strength information is not disclosed. The product works by stimulating insulin release from pancreatic beta cells to help control type 2 diabetes mellitus.

Glimepirid Actavis is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan. It may be used when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be combined with metformin or other antidiabetic agents. - May be prescribed for patients who have not achieved target HbA1c with lifestyle changes alone. - Used as an adjunct to diet and exercise in adults with type 2 diabetes. - May help reduce the need for insulin therapy in some patients.

Glimepirid Actavis may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require prompt medical attention.

Common: - Hypoglycemia (low blood sugar) - Weight gain - Nausea or abdominal discomfort - Headache - Dizziness - Skin rash or itching

Serious: - Severe hypoglycemia leading to loss of consciousness - Allergic reactions such as swelling of the face, lips, or throat - Hepatic dysfunction indicated by jaundice - Hematologic abnormalities like leukopenia or thrombocytopenia

Before starting Glimepirid Actavis, patients should consider several safety factors to minimize risks. Proper assessment and monitoring are essential.

- Assess renal and hepatic function prior to initiation. - Use caution in elderly patients due to increased hypoglycemia risk. - Avoid use in patients with known sulfonylurea hypersensitivity. - Monitor blood glucose regularly to adjust dose as needed. - Counsel patients on recognizing and managing hypoglycemia. - Discuss pregnancy and lactation status with a healthcare provider. - Review concomitant medications that may affect glucose levels.

Glimepirid Actavis can interact with other drugs, altering its effectiveness or increasing the risk of adverse events. Some combinations should be avoided, while others require careful monitoring.

Avoid: - Other sulfonylureas or meglitinides (additive hypoglycemia risk). - Strong CYP2C9 inhibitors such as fluconazole or amiodarone (increase glimepiride levels). - Disulfiram (may potentiate hypoglycemia).

Use with caution: - Beta‑blockers (mask hypoglycemia symptoms). - Thiazide diuretics (may raise blood glucose). - ACE inhibitors or ARBs (potential additive effect on renal function). - Antidepressants like SSRIs (possible glucose variability). - Alcohol (enhances hypoglycemic effect).